OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 507 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR News digest – targeted drug approval, microbubble ‘warheads’ and prostate cancer... June 27, 2020 10 Things Diet Soda Does to Your Body If You Drink... July 29, 2021 Suggesting a Deadline in the Invitation Letter to FIT Colorectal Cancer... March 31, 2025 A Clinical Signal of Efficacy Observed with a Combination of Nivolumab... June 20, 2022 Load more HOT NEWS Καρκίνος Δέρματος Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid... What You Should Know About Receiving Online Medical Test Results and... Hiding in plain sight: How we can use immune cells to...
